Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Dyne Therapeutics, Inc. (DYN)  
$23.70 1.29 (5.14%) as of 4:30 Thu 4/25


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 81,110,000
Market Cap: 1.92(B)
Last Volume: 0 Avg Vol: 0
52 Week Range: $6.62 - $29.18
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    : 21.5
Insider 3/6 Months : 22.1
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Dyne Therapeutics is a muscle disease company focused on developing therapeutics for people living with genetically driven diseases. Co. is developing the following product candidates: DYNE-101, to address the genetic basis of myotonic dystrophy type 1 by targeting the toxic nuclear DMPK RNA that causes the disease; DYNE-251 for patients with mutations amenable to skipping Exon 51, to be followed by the development of therapeutics for patients with mutations amenable to skipping other exons, including Exon 53, 45 and 44; and DYNE-301 to address the genetic basis of facioscapulohumeral dystrophy by reducing DUX4 expression in muscle tissue.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 1,714,285 1,714,285 3,583,447
Total Buy Value $0 $29,999,988 $29,999,988 $50,000,022
Total People Bought 0 1 1 3
Total Buy Transactions 0 1 1 3
Total Shares Sold 4,601,014 5,034,239 5,451,868 5,708,183
Total Sell Value $111,423,214 $119,163,524 $124,434,495 $127,620,166
Total People Sold 9 9 9 9
Total Sell Transactions 53 72 93 103
End Date 2024-01-25 2023-10-24 2023-04-25 2022-04-25

   
Records found: 222
  Page 1 of 9  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Cox John CEO & President   •       •      –    2024-03-25 3/A IO $0.00 $0 D/D 0 5,000     -
   Cox John See Remarks   •       •      –    2024-03-25 3 IO $0.00 $0 D/D 0 10,000 -4%     
   Farwell Wildon Chief Medical Officer   •       –      –    2024-03-12 4 AS $25.58 $26,347 D/D (1,030) 150,560 -12%     
   Mcneill Jonathan Chief Business Officer   •       –      –    2024-03-11 4 AS $25.48 $499,842 D/D (19,601) 139,408 -7%     
   Mcneill Jonathan Chief Business Officer   •       –      –    2024-03-11 4 OE $5.54 $98,751 D/D 17,825 159,009     -
   High Susanna Gatti Chief Operating Officer   •       –      –    2024-03-11 4 AS $25.70 $58,904 D/D (2,292) 156,800 -7%     
   Farwell Wildon Chief Medical Officer   •       –      –    2024-03-11 4 AS $25.70 $40,735 D/D (1,585) 151,590 -7%     
   Brumm Joshua T CEO & President   •       •      –    2024-03-11 4 AS $25.42 $1,704,142 D/D (66,387) 537,998 -7%     
   Brumm Joshua T CEO & President   •       •      –    2024-03-11 4 OE $5.54 $277,000 D/D 50,000 604,385     -
   Scalzo Richard William SVP, Head of Finance & Admin.   •       –      –    2024-03-11 4 AS $24.99 $67,542 D/D (2,672) 119,283 -7%     
   Beskrovnaya Oxana Chief Scientific Officer   •       –      –    2024-03-11 4 AS $25.70 $53,482 D/D (2,081) 152,352 -7%     
   Mcneill Jonathan Chief Business Officer   •       –      –    2024-03-08 4 AS $25.46 $2,361,531 D/D (90,000) 141,184 -5%     
   Mcneill Jonathan Chief Business Officer   •       –      –    2024-03-08 4 OE $5.54 $498,600 D/D 90,000 231,184     -
   High Susanna Gatti Chief Operating Officer   •       –      –    2024-03-08 4 AS $26.66 $725,344 D/D (27,199) 159,092 -5%     
   Brumm Joshua T CEO & President   •       •      –    2024-03-08 4 AS $25.30 $9,421,634 D/D (363,343) 554,385 -5%     
   Brumm Joshua T CEO & President   •       •      –    2024-03-08 4 OE $5.54 $2,012,920 D/D 363,343 917,728     -
   Scalzo Richard William SVP, Head of Finance & Admin.   •       –      –    2024-03-08 4 AS $25.31 $2,261,465 D/D (86,252) 121,955 -5%     
   Scalzo Richard William SVP, Head of Finance & Admin.   •       –      –    2024-03-08 4 OE $5.54 $477,836 D/D 86,252 208,207     -
   Farwell Wildon Chief Medical Officer   •       –      –    2024-03-07 4 AS $25.80 $256,585 D/D (9,921) 153,175 -10%     
   High Susanna Gatti Chief Operating Officer   •       –      –    2024-03-07 4 AS $25.85 $41,127 D/D (1,591) 186,291 -10%     
   Brumm Joshua T CEO & President   •       •      –    2024-03-07 4 AS $25.85 $234,873 D/D (9,086) 554,385 -10%     
   Beskrovnaya Oxana Chief Scientific Officer   •       –      –    2024-03-07 4 AS $25.85 $61,342 D/D (2,373) 154,433 -10%     
   Scalzo Richard William SVP, Head of Finance & Admin.   •       –      –    2024-03-07 4 AS $25.85 $58,757 D/D (2,273) 121,955 -10%     
   Mcneill Jonathan Chief Business Officer   •       –      –    2024-03-07 4 AS $25.85 $62,919 D/D (2,434) 141,184 -10%     
   Rhodes Jason P   –       •      –    2024-03-01 4 AS $30.05 $1,398,347 I/I (46,534) 847,388 -18%     
  222 Records found
  1  2  3  4  5  6  7  8  9   
  Page 1 of 9
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us